source
- InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trialInnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral…
- Republicans block bill to end Medicare AI prior-authorization pilotA Senate vote on Thursday failed to halt a Medicare pilot that uses artificial intelligence to approve or deny care. The measure, backed by Democrats, was rejected by a 46‑to‑50 vote, with Republic…